Abstract: A display substrate, a manufacturing method thereof and a display apparatus are disclosed. The display substrate includes a silicon base substrate and a color film layer disposed on the silicon base substrate. A plurality of metal traces for connecting a display area and a cathode ring with a bonding area respectively are contained in the silicon base substrate. The color film layer includes a first align mark, and the first align mark has a hollowed-out structure. A projection of the first align mark on the silicon base substrate and projections of the metal traces on the silicon base substrate include overlapping areas.

Abstract: The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.

Abstract: Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.

Abstract: The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.

Abstract: Disclosed is a pharmaceutical dosage form including a therapeutically effective amount of an NSAID and an antiulcerative agent.

Abstract: The present invention relates to a novel controlled release dosage form that releases therapeutic amounts of a sedative or hypnotic agent rapidly after administration and maintains therapeutic levels for about eight hours after administration.

Abstract: In certain embodiments, the invention is directed to a pharmaceutical dosage form consisting essentially of a single phase matrix comprising metformin or a pharmaceutically acceptable salt thereof and at least one controlled release excipient; said dosage form providing a mean Tmax of metformin from about 3 to about 12 hours after administration to human patients.

Abstract: The present invention comprises a device and methods for dissolution or immersion testing and, in particular, a device and methods that improve the consistency of test results by limiting the ability of pharmaceutical or other dosage forms to move or reorient during testing.

Abstract: A system and method for receiving and collecting particulate matter from drilled or cut holes in a tablet on a turntable and transporting said particulate to a remote location is described.

Abstract: The present invention comprises a device and methods for dissolution or immersion testing and, in particular, a device and methods that improve the consistency of test results by limiting the ability of pharmaceutical or other dosage forms to move or reorient during testing.

Abstract: The present invention comprises a device and methods for dissolution or immersion testing and, in particular, a device and methods that improve the consistency of test results by limiting the ability of pharmaceutical or other dosage forms to move or reorient during testing.

Abstract: A controlled release oxybutynin tablet that employs a homogeneous core with less than 50% of a water swellable polymer and a semi-permeable membrane that surrounds the homogeneous core.

Abstract: The present invention is directed to sustained release oral dosage forms comprising neutralized divalproex sodium, methods of manufacturing the dosage forms, and methods of treatment with the dosage forms.

Abstract: Disclosed is a controlled release formulation comprising valproic acid, pharmaceutically acceptable salt thereof, amide thereof, or derivative thereof.

Abstract: This invention relates to an apparatus and method for regulating the delivery rate of bulk tablets to a tablet transportation system.

Abstract: The subject invention is a system and method for receiving and collecting particulate matter from a drilled or cut surface and transporting said particulate to a remote location.

Abstract: The present invention comprises a device and methods for dissolution or immersion testing and, in particular, a device and methods that improve the consistency of test results by limiting the ability of pharmaceutical or other dosage forms to move or reorient during testing.

Abstract: Disclosed is a pharmaceutical dosage form including a therapeutically effective amount of an NSAID and an antiulcerative agent.

Abstract: A method for receiving and collecting particulate matter from drilled or cut holes in a tablet on a turntable and transporting said particulate to a remote location is described.

Abstract: In certain embodiments, the invention is directed to a pharmaceutical dosage form consisting essentially of a single phase matrix comprising metformin or a pharmaceutically acceptable salt thereof and at least one controlled release excipient; said dosage form providing a mean Tmax of metformin from about 3 to about 12 hours after administration to human patients.